Jiao Li

Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma

This study identifies fusion-driven oncogenic programs in translocation renal cell carcinoma (tRCC) that shape an immunosuppressive tumor microenvironment, explaining its reduced immunotherapy response.

Detection and monitoring of translocation renal cell carcinoma via plasma cell-free epigenomic profiling

This paper detects and monitors translocation renal cell carcinoma (tRCC) using plasma cell-free epigenomic profiling, achieving high accuracy in distinguishing tRCC from other cancers and healthy controls.

Phenotypic screening converges on CDK9 inhibition as a therapeutic strategy in translocation renal cell carcinoma

The paper identifies CDK9 inhibition as a therapeutic strategy for translocation renal cell carcinoma through phenotypic screening and mechanistic analysis.

Dual Inhibition of CDK4/6 and mTORC1 Establishes a Preclinical Strategy for Translocation Renal Cell Carcinoma

This study identifies CDK4/6 and mTORC1 pathway activation in tRCC and shows that their dual inhibition synergistically suppresses tRCC cell growth in vitro and xenografts in vivo.

TFE3 fusions direct an oncogenic transcriptional program that drives OXPHOS and unveils vulnerabilities in translocation renal cell carcinoma

This study identifies TFE3 fusions driving OXPHOS in tRCC and reveals EGLN1 inhibition as a therapeutic target.

Cancer target discovery enabled by transcriptome-based virtual CRISPR screening

This study uses machine learning to infer gene dependencies from tumor transcriptomes, identifying cancer vulnerabilities in rare cancers without experimental screening.

A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer

This study identifies PRMT1 as a critical regulator of AR signaling in prostate cancer through genome-scale CRISPR screening and shows its potential as a therapeutic target.